NEWS

Three questions to Sarah Bischof, Head of Clinical Operations
1. What are the current main characteristics of clinical trials for cancer treatments? Sarah Bischof: Oncology is a leading area for innovative R&D on many metrics – whether number of...
November 21, 2022
Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...
November 9, 2022
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…

November 3, 2022
Press release: invIOs to present data from clinical stage Cbl-b program at SITC 2022

Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…

October 18, 2022
Press release: invIOs to present at upcoming industry and investor conferences
Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...
October 11, 2022
Cancer – the hallmarks and beyond
Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...
September 26, 2022
Three questions to Mario Kuttke, Head of Cell Therapy
1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...
July 27, 2022
The race against cancer – targeting Cbl-b in cellular therapy
invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...
June 29, 2022
Press release: APEIRON shareholders approve new group structure
geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...
April 26, 2022
Three questions to Alexander Dohnal, Head of Preclinical Development
1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...
April 5, 2022
RNA – in the midst of a medical revolution

Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.

April 5, 2022
Press release: invIOs to present at upcoming conferences
Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...
February 3, 2022
Unlocking the master checkpoint of cancer immunity

Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…

January 28, 2022
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer

1.   Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger:  Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…

January 28, 2022
Press release: invIOs goes live

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…

December 15, 2021
The immune system’s fight against cancer

Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…

December 15, 2021
Perspectives: The Cancer Revolution

Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…

December 14, 2021
Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…

July 6, 2021
Press release: APEIRON Biologics announces changes to management and supervisory boards

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…

June 1, 2021
Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution...
February 3, 2021